Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 08h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter...
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
26 oct. 2023 08h05 HE
|
Agile Therapeutics, Inc.
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it...
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2023 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to...
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 08h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari...
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
09 août 2023 08h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to...
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
26 juil. 2023 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before...
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
26 juin 2023 08h01 HE
|
Agile Therapeutics, Inc.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities...
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
23 juin 2023 12h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today praised the Executive Order issued by President Biden that addresses...
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
15 juin 2023 16h05 HE
|
Agile Therapeutics, Inc.
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch...
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
13 juin 2023 16h05 HE
|
Agile Therapeutics, Inc.
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail...